v3.25.3
Income Taxes
9 Months Ended
Sep. 30, 2025
Income Taxes  
Income Taxes

Note 7. Income Taxes

​

Effective January 1, 2024, Southland Holdings, LLC and subsidiary filing group elected to join the Southland Holdings, Inc. and Subsidiaries filing group to have all domestic corporate entities included within one consolidated federal income tax return starting with the 2024 calendar year.

​

The federal statutory tax rate is 21%. Southland’s effective tax rate was (289.0%) and 22.9% for the three months ended September 30, 2025 and 2024, respectively. The primary differences between the statutory rate and the effective rate for the three months ended September 30, 2025 and 2024 were due to state income taxes, federal tax credits, valuation allowances recorded against domestic subsidiaries’ net deferred tax assets, and income earned in a foreign jurisdiction with different income tax rates from the domestic rate; however, that foreign income is included within U.S. taxable income through Section 951A Global Intangible Low-Taxed Income (“GILTI”). The effective tax rate was (173.0%) and 24.2% for the nine months ended September 30, 2025 and 2024, respectively. The primary differences between the statutory rate and the effective rate for the nine months ended September 30, 2025 and 2024 were due to state income taxes, federal tax credits, valuation allowances recorded against domestic subsidiaries’ net deferred tax assets, and income earned in a foreign jurisdiction with different income tax rates from the domestic rate; however, that foreign income is included within U.S. taxable income through GILTI.

​

The Company is in a net deferred tax asset position for both U.S. federal and state income tax as of September 30, 2025. The Company assesses available positive and negative evidence to estimate whether sufficient taxable income will be generated to permit use of existing deferred income tax assets. The Company has incurred three years of cumulative losses in various jurisdictions including the U.S. Such objective evidence and recent changes in forecasts resulted in the Company establishing a valuation allowance against the net deferred tax assets related to U.S. federal and state income tax as of September 30, 2025, with the exception of the net deferred tax assets related to separate state filings for certain subsidiaries. As of September 30, 2025, the Company has recorded a valuation allowance of approximately $62.5 million related to its US federal and state net deferred tax assets, inclusive of current year activity, as they are determined to be more-likely-than-not to not be utilized.

​

As a result of financial losses incurred within the Canadian operations at certain subsidiaries, the Company maintains a valuation allowance against the net deferred tax assets as they are determined to not be more-likely-than-not to be utilized. As of September 30, 2025, the Company has a valuation allowance in the amount of $8.3 million related to the net deferred tax assets on certain Canadian subsidiaries.

​

The Company maintains a valuation allowance related to the net deferred tax assets recorded from United Kingdom operations from historic losses incurred that are determined to not be more-likely-than-not to be utilized. As of September 30, 2025, the valuation allowance related to United Kingdom operations is $16.6 million.

​

On July 4, 2025, the President signed into law the One Big Beautiful Bill Act (the “Tax Act”). The Tax Act introduces multiple tax laws and other legislative changes, including modifications to income tax provisions such as domestic research and development expenses, capital expenditures, adjustments to business interest expense limitation calculation, and U.S. taxation of international earnings. These provisions do not have any current impact on our consolidated financial statements. However, we expect the Tax Act to allow the Company to accelerate previously capitalized R&D expenditures as well as provide favorable changes to the business interest expense limitation calculation and removal of the requirement to capitalize R&D expenditures in current year and going forward.

​